RIP3-MLKL Pathway Blocker for Skin Necroptosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective therapeutic agents for necroptosis-related skin diseases, such as drug-induced skin conditions like Stevens-Johnson syndrome and toxic epidermal necrolysis, due to the lack of understanding of the necroptosis mechanism and molecular targets.
Innovation Solution
Administering a receptor-interacting protein kinase-3 (RIP3)-mixed lineage kinase domain-like protein (MLKL) pathway blocker, specifically dabrafenib, to inhibit RIP3 overexpression and MLKL phosphorylation, thereby preventing cell death via necroptosis in skin tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If caspase inhibitors are developed based on apoptosis research, then pharmaceutical development effort is increased, but no effective drugs are approved for necroptosis diseases
Solution Approach 1:
The patent changes the fundamental parameter of cell death mechanism from apoptosis to necroptosis, and consequently changes the therapeutic target from caspase to RIP3-MLKL pathway. This parameter change enables the development of effective drugs for necroptosis diseases that were previously untreatable.
Solution Approach 2:
The patent extracts the harmful necroptosis pathway from the previously studied apoptosis pathway, identifying RIP3 and MLKL as specific targets. By separating and focusing on the necroptosis mechanism, the patent enables selective drug development that avoids the failures of broad caspase inhibition.
2Reliability
If necroptosis mechanism is not understood, then therapeutic agent development is delayed, but necroptosis-related skin diseases remain incurable
Solution Approach 1:
The patent performs preliminary research and identification of the RIP3-MLKL pathway as the critical necroptosis mechanism before developing therapeutic agents. This preliminary action establishes the scientific foundation and target validation, enabling subsequent drug development to proceed efficiently without time loss.
Solution Approach 2:
The patent introduces RIP3 and MLKL as intermediary molecular targets between the necroptosis stimulus and the harmful cell death outcome. By intervening at these specific molecular points, the patent creates effective therapeutic agents that can block the necroptosis pathway.
3Reliability
If RIP3-MLKL pathway is blocked, then skin necroptosis diseases are effectively treated, but new therapeutic agents must be developed
Solution Approach 1:
The patent identifies the RIP3-MLKL pathway as a universal mechanism underlying multiple skin necroptosis diseases, including drug-induced skin conditions. By developing inhibitors that target this common pathway, the patent creates multi-functional therapeutic agents that can treat various disease manifestations simultaneously.
Solution Approach 2:
The patent segments the necroptosis pathway into distinct components (RIP3 kinase and MLKL effector) that can be targeted by different types of inhibitors. This segmentation allows for the development of specialized therapeutic agents with specific mechanisms of action, improving both efficacy and manufacturability.
Data Source
AI summary
The present invention relates to methods of preventing or treating skin necroptosis diseases, including administering to subjects receptor-interacting protein kinase-3 (RIP3)-mixed lineage kinase domain-like protein (MLKL) pathway blockers or dabrafenib, and method of diagnosing of skin necroptosis diseases, including detecting phosphorylated MLKL. The RIP3-MLKL pathway blockers according to the present invention directly suppress RIP3 overexpressing in skin necroptosis diseases, or inhibit phosphorylation and translocation to plasma membranes of MLKL, subsequently induced therefrom, thereby effectively preventing skin cell death via necroptosis. Thus, the present invention can prevent or treat a variety of skin diseases caused by necroptosis.